Gain Therapeutics (GANX) Expected to Announce Quarterly Earnings on Wednesday

Gain Therapeutics (NASDAQ:GANX) is expected to post its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect Gain Therapeutics to announce earnings of ($0.13) per share and revenue of $0.03 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Gain Therapeutics (NASDAQ:GANX) last released its earnings results on Tuesday, August 11th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.03. On average, analysts expect Gain Therapeutics to post ($0.50) EPS for the current fiscal year and ($0.55) EPS for the next fiscal year.

Gain Therapeutics Trading Up 1.8%

GANX stock opened at $1.15 on Wednesday. The company has a quick ratio of 4.36, a current ratio of 4.36 and a debt-to-equity ratio of 0.02. Gain Therapeutics has a twelve month low of $1.11 and a twelve month high of $4.34. The company has a market cap of $50.19 million, a P/E ratio of -2.30 and a beta of 0.29. The business has a fifty day moving average of $1.59 and a 200-day moving average of $1.85.

Analyst Upgrades and Downgrades

GANX has been the topic of several recent research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Gain Therapeutics in a report on Friday, September 4th. BTIG Research reissued a “buy” rating and set a $5.00 price objective on shares of Gain Therapeutics in a report on Monday, October 5th. Finally, HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Gain Therapeutics in a research report on Monday, October 5th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $7.67.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc is a biotechnology company focused on developing small-molecule therapies for diseases associated with lysosomal dysfunction, including neurodegenerative and rare disorders. The company’s approach is designed to identify compounds that bind to and modulate disease-related proteins, with the goal of restoring their function and addressing underlying disease mechanisms.

Gain Therapeutics’ lead investigational program, GT-02287, is an orally administered, brain-penetrant small molecule being developed for GBA1-associated Parkinson’s disease.